Carl Peck, MD

Title(s)Professor, Bioengineering
SchoolSchool of Pharmacy
Address550 16th Street, #001
San Francisco CA 94158
Phone202-427-7660
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The Role of Model Master Files for Sharing, Acceptance, and Communication with FDA. AAPS J. 2024 02 27; 26(2):28. Fang L, Gong Y, Hooker AC, Lukacova V, Rostami-Hodjegan A, Sale M, Grosser S, Jereb R, Savic R, Peck C, Zhao L. PMID: 38413548.
      View in: PubMed   Mentions: 1     Fields:    
    2. Comparing a Bayesian Approach (BEST) with the Two One-Sided t-Tests (TOSTs) for Bioequivalence Studies. AAPS J. 2022 Sep 01; 24(5):97. Peck C, Campbell G, Yoo I, Feng K, Hu M, Zhao L. PMID: 36050426.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Probability of Success: A Crucial Concept to Inform Decision Making in Pharmaceutical Research and Development. Clin Pharmacol Ther. 2022 05; 111(5):1001-1003. Lalonde RL, Peck CC. PMID: 34951934.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    4. Farewell to our Wonderful Friend and Colleague, J. Richard (Dick) Crout (1929-2020). Clin Pharmacol Ther. 2021 06; 109(6):1384-1387. Temple RJ, O'Neill RT, Peck CC. PMID: 33111972.
      View in: PubMed   Mentions:    Fields:    
    5. Scientific considerations for global drug development. Sci Transl Med. 2020 07 29; 12(554). Wilson JL, Cheung KWK, Lin L, Green EAE, Porrás AI, Zou L, Mukanga D, Akpa PA, Darko DM, Yuan R, Ding S, Johnson WCN, Lee HA, Cooke E, Peck CC, Kern SE, Hartman D, Hayashi Y, Marks PW, Altman RB, Lumpkin MM, Giacomini KM, Blaschke TF. PMID: 32727913; PMCID: PMC8158457.
      View in: PubMed   Mentions: 6     Fields:    
    6. Sir Alasdair Breckenridge 1937-2019. A Celebratory Tribute. Clin Pharmacol Ther. 2020 07; 108(1):22-25. Peck CC, Breckenridge RA. PMID: 32279311.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation. Br J Clin Pharmacol. 2019 09; 85(9):1874-1877. Breckenridge AM, Breckenridge RA, Peck CC. PMID: 31290181; PMCID: PMC6710497.
      View in: PubMed   Mentions: 12     Fields:    
    8. Bayesian Approach to Establish Bioequivalence: Why and How? Clin Pharmacol Ther. 2019 02; 105(2):301-303. Peck CC, Campbell G. PMID: 30666630.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics. Physiol Rep. 2018 03; 6(5). Aksenov S, Peck CC, Eriksson UG, Stanski DR. PMID: 29488355; PMCID: PMC5828935.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    10. Farewell to Our Good Friend, Outstanding Mentor, and Colleague Darrell R. Abernethy (1949-2017). Clin Pharmacol Ther. 2018 04; 103(4):552-555. Schwartz JB, Woosley RL, Peck CC. PMID: 29435985.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Poor medication adherence in clinical trials: consequences and solutions. Nat Rev Drug Discov. 2017 03; 16(3):149-150. Breckenridge A, Aronson JK, Blaschke TF, Hartman D, Peck CC, Vrijens B. PMID: 28154411.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    12. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther. 2016; 10:4005-4016. Suh HY, Peck CC, Yu KS, Lee H. PMID: 27994442; PMCID: PMC5153257.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    13. Farewell to our Good Friend and Outstanding Colleague David Flockhart (1952-2015). Clin Pharmacol Ther. 2016 Feb; 99(2):139-42. Peck CC, Woosley RL. PMID: 26800329.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years. J Pharm Sci. 2012 Nov; 101(11):4075-99. Rowland M, Noe CR, Smith DA, Tucker GT, Crommelin DJ, Peck CC, Rocci ML, Besançon L, Shah VP. PMID: 22911654.
      View in: PubMed   Mentions: 3     Fields:    
    15. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011; 51:45-73. Rowland M, Peck C, Tucker G. PMID: 20854171.
      View in: PubMed   Mentions: 207     Fields:    Translation:HumansAnimals
    16. Quantitative clinical pharmacology is transforming drug regulation. J Pharmacokinet Pharmacodyn. 2010 Dec; 37(6):617-28. Peck CC. PMID: 20978827.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    17. A roadmap for biomarker qualification. Nat Biotechnol. 2010 May; 28(5):444-5. Warnock DG, Peck CC. PMID: 20458313.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    18. Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer. 2008 Jan; 44(1):8-11. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. PMID: 17981025; PMCID: PMC2673461.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    19. "Getting the dose right": facts, a blueprint, and encouragements. Clin Pharmacol Ther. 2007 Jul; 82(1):12-4. Peck CC, Cross JT. PMID: 17571068.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    20. Preventing postmarketing changes in recommended doses and marketing withdrawals. Ernst Schering Res Found Workshop. 2007; (59):209-16. Peck C. PMID: 17117726.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update. Eur J Pharm Sci. 2007 Feb; 30(2):107-12. Rolan P, Danhof M, Stanski D, Peck C. PMID: 17196378.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. Simulation of correlated continuous and categorical variables using a single multivariate distribution. J Pharmacokinet Pharmacodyn. 2006 Dec; 33(6):773-94. Tannenbaum SJ, Holford NH, Lee H, Peck CC, Mould DR. PMID: 17053984.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    23. Evidence of effectiveness: how much can we extrapolate from existing studies? AAPS J. 2005 Oct 05; 7(2):E467-74. Lee H, Yim DS, Zhou H, Peck CC. PMID: 16353924; PMCID: PMC2750984.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    24. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2005 Mar; 45(3):246-56. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. PMID: 15703360.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    25. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci. 2004 Feb 09; 6(1):E6. Rowland M, Balant L, Peck C. PMID: 15198507; PMCID: PMC2750941.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    26. Randomized concentration-controlled trials: motivations, use, and limitations. Clin Pharmacol Ther. 2003 Sep; 74(3):203-14. Kraiczi H, Jang T, Ludden T, Peck CC. PMID: 12966364.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    27. Postmarketing drug dosage changes. Pharmacoepidemiol Drug Saf. 2003 Jul-Aug; 12(5):425-6. Peck CC. PMID: 12899120.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin Pharmacol Ther. 2003 Jun; 73(6):481-90. Peck CC, Rubin DB, Sheiner LB. PMID: 12811358.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    29. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003 Apr; 73(4):348-65. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. PMID: 12709725.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    30. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf. 2002 Sep; 11(6):439-46. Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C. PMID: 12426927.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    31. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther. 2001 Jun; 69(6):387-99. Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW, Peck CC. PMID: 11406736.
      View in: PubMed   Mentions: 6     Fields:    
    32. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther. 2000 Nov; 68(5):568-77. Kimko HC, Reele SS, Holford NH, Peck CC. PMID: 11103759.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    33. Biological sex analysis in clinical research. J Womens Health Gend Based Med. 2000 Nov; 9(9):933-4. Woosley RL, Anthony M, Peck CC. PMID: 11103088.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res. 2000 Nov; 17(11):1335-44. Lesko LJ, Rowland M, Peck CC, Blaschke TF. PMID: 11205725.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    35. A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep. Clin Pharmacol Ther. 2000 Aug; 68(2):175-88. Karlsson MO, Schoemaker RC, Kemp B, Cohen AF, van Gerven JM, Tuk B, Peck CC, Danhof M. PMID: 10976549.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    36. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. J Clin Pharmacol. 2000 Aug; 40(8):803-14. Lesko LJ, Rowland M, Peck CC, Blaschke TF. PMID: 10934664.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    37. Assessment and reporting of clinical pharmacology information in drug labeling. Clin Pharmacol Ther. 2000 Mar; 67(3):196-200. Spyker DA, Harvey ED, Harvey BE, Harvey AM, Rumack BH, Peck CC, Atkinson AJ, Woosley RL, Abernethy DR, Cantilena LR. PMID: 10741621.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    38. Simulation of clinical trials. Annu Rev Pharmacol Toxicol. 2000; 40:209-34. Holford NH, Kimko HC, Monteleone JP, Peck CC. PMID: 10836134.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    39. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur J Pharm Sci. 2000; 10(4):iv-xiv. Lesko LJ, Rowland M, Peck CC, Blaschke TF, Breimer D, de Jong HJ, Grahnen A, Kuhlmann JJ, Stewart B. PMID: 11023342.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    40. Dr Marcus M. Reidenberg, recipient of the 1999 Harry Gold Award. Clin Pharmacol Ther. 1999 Jul; 66(1):1. Atkinson AJ, Moore KE, Peck CC. PMID: 10430102.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Treatment of tobacco dependence: innovative regulatory approaches to reduce death and disease: preface. Food Drug Law J. 1998; 53 suppl:1-8. Warner KE, Peck CC, Woosley RL, Henningfield JE, Slade J. PMID: 10342978.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    42. Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep. Clin Pharmacol Ther. 1997 Oct; 62(4):444-52. Tuk B, Oberyé JJ, Pieters MS, Schoemaker RC, Kemp B, van Gerven J, Danhof M, Kamphuisen HA, Cohen AF, Breimer DD, Peck CC. PMID: 9357396.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    43. Drug development: improving the process. Food Drug Law J. 1997; 52(2):163-7. Peck CC. PMID: 10557553.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    44. The essential role of integrative biomedical sciences in protecting and contributing to the health and well-being of our nation. Physiologist. 1994 Jun; 37(3):79-86. Jobe PC, Adams-Curtis LE, Burks TF, Fuller RW, Peck CC, Ruffolo RR, Snead OC, Woosley RL. PMID: 8073080.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    45. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Clin Pharmacol. 1994 Feb; 34(2):111-9. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al. PMID: 8163710.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    46. Understanding consequences of concurrent therapies. JAMA. 1993 Mar 24-31; 269(12):1550-2. Peck CC, Temple R, Collins JM. PMID: 8445821.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    47. Dog mastocytoma cells produce transforming growth factor beta 1. J Clin Invest. 1992 Jul; 90(1):35-41. Pennington DW, Lopez AR, Thomas PS, Peck C, Gold WM. PMID: 1634619; PMCID: PMC443060.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    48. Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther. 1992 Jul; 52(1):11-23. Cooper MR, Lieberman R, La Rocca RV, Gernt PR, Weinberger MS, Headlee DJ, Kohler DR, Goldspiel BR, Peck CC, Myers CE. PMID: 1623689.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    49. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm Res. 1992 Jun; 9(6):826-33. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al. PMID: 1409369.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    50. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci. 1992 Jun; 81(6):605-10. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al. PMID: 1355792.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    51. Clinical pharmacology training at the Food & Drug Administration. J Clin Pharmacol. 1992 May; 32(5):400-6. Nelson RC, Peck CC. PMID: 1587956.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther. 1992 Apr; 51(4):465-73. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al. PMID: 1563216.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimals
    53. The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Control Clin Trials. 1991 Dec; 12(6):780-94. Sanathanan LP, Peck CC. PMID: 1665119.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    54. Chronobiology. Suggestions for integrating it into drug development. Ann N Y Acad Sci. 1991; 618:563-71. Harter JG, Peck CC. PMID: 2006810.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    55. FDA regulation of prescription drug advertising. JAMA. 1990 Nov 14; 264(18):2424-5. Peck CC, Rheinstein PH. PMID: 2232001.
      View in: PubMed   Mentions: 1     Fields:    
    56. FDA's position on the clozaril patient management system. Hosp Community Psychiatry. 1990 Aug; 41(8):876-7. Peck CC. PMID: 2401475.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    57. Transcutaneous theophylline collection in preterm infants. Clin Pharmacol Ther. 1990 Apr; 47(4):427-34. Murphy MG, Peck CC, Conner DP, Zamani K, Merenstein GB, Rodden D. PMID: 2328550.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    58. Methodological issues in AIDS clinical trials. Discussion. Design of clinical trials--approaches to clinical trials design. J Acquir Immune Defic Syndr (1988). 1990; 3 Suppl 2:S27-36 discussion S37-9. Lietman P, Temple R, Harrington M, Peck C. PMID: 2231299.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. 'Vasoconstriction'--skin blanching--assay for glucocorticoids--a critique. Arch Dermatol. 1989 Nov; 125(11):1558-61. Shah VP, Peck CC, Skelly JP. PMID: 2817920.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    60. Understanding comparisons of drug introductions between the United States and the United Kingdom. Clin Pharmacol Ther. 1989 Aug; 46(2):139-45. Coppinger PL, Peck CC, Temple RJ. PMID: 2758723.
      View in: PubMed   Mentions: 1     Fields:    
    61. Clinical utility of a Bayesian dosing program for phenytoin. Ther Drug Monit. 1989; 11(3):285-94. Privitera MD, Homan RW, Ludden TM, Peck CC, Vasko MR. PMID: 2728087.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    62. Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance. Ther Drug Monit. 1989; 11(4):455-62. Killilea T, Coleman R, Ludden T, Peck CC, Rose D. PMID: 2741195.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    63. Clinical assessment of a two-compartment Bayesian forecasting method for lidocaine. Ther Drug Monit. 1988; 10(1):74-9. Beach CL, Farringer JA, Peck CC, Crawford MH, Ludden TM, Clementi WA. PMID: 3376185.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    64. Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentration. Clin Pharm. 1986 Jul; 5(7):580-5. Ludden TM, Beal SL, Peck CC, Godley PJ. PMID: 3755661.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    65. Current status of clinical pharmacology training in the United States. Clin Pharmacol Ther. 1986 Apr; 39(4):451-8. Peck CC, Crout JR. PMID: 3956065.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J Pharm Sci. 1985 Feb; 74(2):171-4. Perlin E, Smith CG, Nichols AI, Almirez R, Flora KP, Cradock JC, Peck CC. PMID: 2985774.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    67. Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data. J Pharmacokinet Biopharm. 1984 Oct; 12(5):545-58. Peck CC, Beal SL, Sheiner LB, Nichols AI. PMID: 6520748.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    68. The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab Rev. 1984; 15(1-2):133-48. Peck CC, Sheiner LB, Nichols AI. PMID: 6745079.
      View in: PubMed   Mentions: 18     Fields:    
    69. Pharmacokinetics and pharmacodynamics of 1,25-dihydroxyvitamin D3 in the chick. Endocrinology. 1982 Sep; 111(3):939-46. Bikle DD, Peck CC, Holford NH, Zolock DT, Morrissey RL. PMID: 6896685.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    70. Normal pharmacokinetics of doxapramin in a patient with renal failure and hypothyroidism. Br J Clin Pharmacol. 1981 Mar; 11(3):305-7. Baker JR, Peck CC, Raybuck BD, Owens EL, Schuster BG. PMID: 7213532; PMCID: PMC1401610.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. General method for determining macrodissociation constants of polyprotic, amphoteric compounds from solubility measurements. J Pharm Sci. 1978 Jan; 67(1):12-6. Peck CC, Benet LZ. PMID: 22738.
      View in: PubMed   Mentions: 4     Fields:    
    72. Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations. Ann Intern Med. 1975 May; 82(5):619-27. Sheiner LB, Halkin H, Peck C, Rosenberg B, Melmon KL. PMID: 1137256.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    73. Determinants of the renal clearance of digoxin. Clin Pharmacol Ther. 1975 Apr; 17(4):385-94. Halkin H, Sheiner LB, Peck CC, Melmon KL. PMID: 1122680.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    74. Differences in serum digoxin concentrations between outpatients and inpatients: an effect of compliance? Clin Pharmacol Ther. 1974 Mar; 15(3):239-46. Sheiner LB, Rosenberg B, Marathe VV, Peck C. PMID: 4593118.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    75. Computer-assisted digoxin therapy. N Engl J Med. 1973 Aug 30; 289(9):441-6. Peck CC, Sheiner LB, Martin CM, Combs DT, Melmon KL. PMID: 4763409.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    Carl's Networks
    Concepts (260)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (7)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-4-g3cb31450 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.